PhRMA | Behind the 340B Drug Pricing Program

The 340B Drug Pricing Program

Oversight and Investigations Subcommittee Hearing: “Oversight of 340B Drug Pricing Program”

Is the 340B program the next 'Too Big To Fail?' - Medical Debt 60-Second Commercial

Abuses of the 340B program are costing taxpayers millions of dollars, all while hospitals profit off of discounts meant for low-income patients. We can’t let these egregious abuses go on any longer. #Fix340B https://www.cagw.org/340B | Citizens Against Government Waste

The federal 340B program requires drug makers to sell their products to some hospitals at a discount. Hospitals and contract pharmacies can then resell them and pocket the difference. It’s a case of the government picking winners (hospitals) and losers (drug manufacturers) among private market participants. Hospitals argue that they need the money to help patients. That is, they use the extra revenue from the program to cut costs or provide free care for those in need. But Jarrett Skorup of the

Perspectives on the 340B Drug Pricing Program | The U.S. Senate Committee on Health, Education, Labor & Pensions

340B Drug Pricing Program Compliance | JD Supra